



V2G
VACCINES 2 GO, Inc.
HEALTH TECHNOLOGIES


Mobile testing &
analysis for COVID-19

Multi test, vaccination
& immunization
management platform

Our Services

- We provide rapid PCR², rapid antibody (IgG/IgM), or saliva as the initial testing modality on site with proficient operators using top of the line equipment to provide testing¹
- Each COVID-19 test (rapid PCR, rapid antibody or saliva) includes:
 - Nasopharyngeal testing swab, blood sample collection or saliva sample collection
 - Mobile PCR lab test, rapid antibody test or saliva lab test
 - Test administration by one of our 40,000 trained nurses across the country
 - vi-TRAK mobile application for data tracking, reporting and storage
- The vi-TRAK system provides a seamless COVID-19 testing and control experience that conveniently tracks, manages and stores all relevant data, available in real-time
- Our system can run 64 rapid PCR tests per lab, per hour. Each location can use multiple mobile PCR testing units to increase frequency of tests administered. For example, five tabletop mobile PCR testing units can administer and analyze 320 tests per hour on location.
- Vaccines2Go will provide on-site supervision of the testing locale during COVID-19 testing as required by SAG

Our Services Continued



PCR Analysis

- Test analysis occurs using portable PCR unit
- Capacity of up to 64 tests every hour
- Uses highly accurate equipment
- Requires specialized training and education
- Test result turnaround is one hour
- Fully automated test data collection
- Data available for patient care & policy making



Antibody Testing

- On-site diagnostics and reporting
- Capacity to analyze millions of test simultaneously
- Highly cost-effective
- Easy to use, requires minimal training to operate
- Test turnaround is 15 minutes, seconds for analysis
- Fully automated test data collection
- Data available for patient care & policy making



Saliva Testing

- Testing occurs in approved labs
- Samples are amplified in-lab and tested via PCR to detect SARS-CoV-2 nucleic acid
- Uses highly accurate equipment
- Requires specialized training and education
- Fully automated test data collection
- Data available for patient care & policy making



Vaccines2Go offers multiple testing modalities to suit the needs of any testing locale.

Our Services Continued

01

Testing

- Rapid Finger Blood
- Saliva Test
- Oral Throat
- PCR Local Lab 24 Hours
- PCR Test Machine ON SITE
- PCR LOCAL STAT TESTING

02

Additional Testing (if necessary)

- ANTIBODY send to lab
- Temperature on site per hour

03

On Site Personnel

- RN Licensed in the State
- DR Licensed in the State
- Administrator/Paperwork
- PA Licensed in the State
- NP Licensed in the State

04

Use of COVID-19 TESTING MACHINE

- PCR Machine on site
- FedEx Overnight Shipping
- Physician Oversight
- Use of vi-TRAK application
- vi-TRAK licensing agreement

05

Tailored Concierge Service

- Customized as per client preference, testing, staffing, equipment, other

06

COVID-19 Vaccination Management

- Services will be available upon release of COVID vaccine

PCR Test Process



SWAB

A nasopharyngeal swab is used by a nurse to collect a sample from a patient



AMPLIFICATION




The sample is prepared by being placed in a solution which amplifies regions of the genome being analyzed



ANALYSIS

After amplification, the sample is placed in an rRT-PCR machine on site for analysis

COVID Rapid Antigen Detection



*Results from early clinical trials. These statements have not been evaluated by the FDA.

Rapid Antigen Testing in 15 Minutes at the Point of Care.

Providers can test for the SARS-CoV-2 antigen in a point of care setting and get results within 15 minutes with a nasal swab and no additional equipment.

For Professional Use Only. For Emergency Authorization Use Only. Qualitative results in 15 minutes from a nasopharyngeal swab. Negative results do not rule out SARS-CoV-2 infection and should be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of patients recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary for patient management.

Pinnacle covid RAD Rapid Antigen Detection Test

This kit contains 25 complete test kits, 25 extraction tubes, 25 dropper tips, work station, package insert and PBS buffer solution

PINNACLE
BIOLABS


COVID Rapid Antigen Detection

- Results in 15 minutes.
- 95% less expensive than laboratory COVID-19 testing.
- Nasal sampling.
- An effective mass-screening protocol.


COVID

Rapid Antigen Detection

Easy Prep



15 Minute Results



Easy to Interpret



COMPANY PROFILE



Pinnacle BioLabs is a privately held corporation started in 2011 as a point-of-care in vitro diagnostics manufacturer of colorectal cancer test kits, drug of abuse testing, and various other disease states via urinalysis. Pinnacle Biolabs is a US Food and Drug Administration certified manufacturer of in vitro diagnostic test kits. US FDA Registration Number: 3010982075. National Provider Identification Number (NPI): 1497269120. Recognizing socio-economic changes, Pinnacle's OTC division received the first and only OTC clearance for a colon cancer detection test, the patented Second Generation FIT®. Within three years of FDA clearance, the Second Generation FIT® became the number one colon cancer test kit in both units sold and total revenue in North America.

Saliva Test Process



SAMPLE

A sterile container is used to collect a saliva sample from a patient



AMPLIFICATION

The sample is prepared by being placed in a solution which amplifies regions of the genome being analyzed




ANALYSIS

After amplification, the sample is placed in an rRT-PCR machine on site for analysis

COVID-19 PCR Test

- The COVID-19 RT-PCR test is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens collected from suspected COVID-19 case individuals.
- This test provides results that identify the presence of SARS-CoV-2 RNA which is generally detectable in respiratory specimens during the acute phase of infection.
- Positive results are indicative of the presence of SARS-CoV-2 RNA and are used in conjunction with clinical diagnosis, patient medical history and other diagnostic information in order to determine patient infection status.
- Combining PCR test results with Rapid Antibody test results provide highly accurate results by reducing the likelihood of Type I & Type II errors that either test would have on its own.

COVID-19 IgG/IgM Antibody Test



96.4%
Sensitivity

98.7%
Specificity

98.1%
Accuracy

- This type of test is a qualitative immunoassay designed to rapidly detect the IgG/IgM antibodies for COVID-19 using human venipuncture (finger prick) whole blood, serum or plasma.
- Immunoglobulin M (IgM) is the body's first line of defense when combating a new viral or bacterial infection. Primarily found in blood and lymph, this the most common antibody produced by the body.
- Immunoglobulin G (IgG) is created in response to a specific antigen (virus) and is significantly more effective at fighting off an infection than IgM. The IgG is considered to be the main factor responsible for long term immunity.
- The presence of IgM indicates recent exposure to the SARS-CoV-2 virus while IgG indicates the patient has reached a further stage of the infection. The combined antibody test is widely accepted as a suitable tool for establishing the presence and progress of COVID-19 but may need to be confirmed via PCR in some cases.


COVID-19 Saliva Test

- The COVID-19 Saliva test uses a sample of saliva collected from a patient that is amplified and analyzed via PCR for SARS-CoV-2 DNA.
- Saliva is first treated with proteinase K followed by heat inactivation before being reverse transcribed into cDNA and amplified/analyzed by RT-PCR to detect the presence of SARS-CoV-2.
- Positive results are indicative of the presence of SARS-CoV-2 RNA and are used in conjunction with clinical diagnosis, patient medical history and other diagnostic information in order to determine patient infection status.
- Multiple controls are used to establish the validity of each test and each must be successful to consider the test successful
- Combining PCR test results with Rapid Antibody test results provide highly accurate results by reducing the likelihood of Type I & Type II errors that either test would have on its own.

viTRAK COVID-19 Testing & Management System




Mobile Application



- vi-TRAK delivers a solution to the largest public health crisis America has faced in decades - tracking and preventing the spread of COVID-19
- HIPAA and HITECH compliant means data is processed under the strictest of regulations to provide security that you can rely on
- vi-TRAK rapidly identifies test results, provides reports, and stores data for further use by healthcare professionals and policy makers - all in real-time

System Management Web Portal



- Customizable dashboard that displays relevant insights and analytics about the data collected from testing
- Can be configured to meet any needs or requirements by system administrator
- Dashboard provides access to all pages in vi-TRAK system such as patient, payment, and contract portals

... why vi-TRAK?

1

The vi-TRAK system is designed to streamline the mass screening process and accelerate the reopening of America in a safe manner

2

Using vi-TRAK in conjunction with confirmatory lab tests achieves efficiency and accuracy within the CDC's and FDA's compulsory data intake and reporting mandates

3

vi-TRAK provides analytics and insights to be used in patient care, epidemiological studies, and policy making

4

Data that is produced can be used for real-time contact tracing to help mitigate the spread of COVID-19

5

Easily scalable platform that can be deployed rapidly for collecting population-level epidemiological data



*CDC compliant full registration of patient under approved health care professional from oversight to administration of testing and vaccinations
**Rapid PCR returns results in one hour



The logo features the letters 'V2G' in a large, bold, dark blue font with a yellow outline. The letter 'O' is replaced by a white globe with green continents. A dark blue airplane with 'V2G' on its side is flying over the globe. Below this graphic, the text 'VACCINES 2 GO, Inc.' is written in a bold, yellow, sans-serif font with a dark blue outline.

VACCINES 2 GO, Inc.

JODY STEWART - CEO & President, Vaccines2Go, vi-TRAK
4060 John Creek Parkway Suite H, Suwanee, GA 30024 | +1.770.896.8284 | info@vi-trak.com

www.vaccines2go.com

www.vi-trak.com



Partners, Clients & Affiliates

